Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage. Keros Therapeutics, Inc. is based in LEXINGTON, MA.
| Revenue (Most Recent Fiscal Year) | $244.06M |
| Net Income (Most Recent Fiscal Year) | $87.01M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 6.42 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.75 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 2.38 |
| Pre-Tax Margin (Trailing 12 Months) | -272.15% |
| Net Margin (Trailing 12 Months) | -256.60% |
| Return on Equity (Trailing 12 Months) | -17.04% |
| Return on Assets (Trailing 12 Months) | -15.84% |
| Current Ratio (Most Recent Fiscal Quarter) | 22.61 |
| Quick Ratio (Most Recent Fiscal Quarter) | 22.62 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $15.51 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.21 |
| Earnings per Share (Most Recent Fiscal Year) | $2.30 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.01 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 19.79M |
| Free Float | 15.71M |
| Market Capitalization | $213.16M |
| Average Volume (Last 20 Days) | 0.33M |
| Beta (Past 60 Months) | 0.94 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 20.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 71.56% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |